MedBulletinsAura Celeste
Orthopedics

Monthly orthopedics and trauma bulletin — September 29, 2026

🎧 Listen to this issueAudio newscast · 5:16 min

Period covered: August 30 to September 29, 2026. Note for the month: it was a thin month for clinical data we could confirm at the original source, and several items come from manufacturer press releases. We publish 5 verified items rather than filler. Curated by Aura Celeste.

Arthroplasty and reconstructive surgery

1. FDA clears Smith+Nephew's LANDMARK total knee system

[Regulatory FDA] [United Kingdom / Canada]
On September 22, Smith+Nephew announced FDA 510(k) clearance of the LANDMARK total knee system, with a fully 3D-printed femoral component (CONCELOC technology) designed to work with the CORI handheld robot. The first case was performed by design surgeon Steven MacDonald in London, Ontario (Canada). The company plans a phased launch, with broad availability through 2027.
Why it matters: this is a manufacturer press release citing internal reports and meeting abstracts, with no published clinical data; the quoted surgeons are implant designers. It does not change practice, and availability in the Dominican Republic is not imminent.
https://orthospinenews.com/2026/09/22/natural-design-amplified-smithnephew-announces-fda-510k-clearance-and-first-surgical-case-of-landmark%E2%97%8A-total-knee-system/

This month there were no new clinical studies verifiable at source in primary or revision arthroplasty or periprosthetic joint infection.

Trauma and fractures

This month there were no new trials or studies with numbers verifiable at source in hip fracture, fracture fixation or polytrauma.

Spine, shoulder, sports medicine and arthroscopy

2. Oral contraceptive use at the time of ACL reconstruction and lower risk of repeat reconstruction

[Publication] [Country not stated in the source] [Outside the period: August 27]
A retrospective cohort study published in Sports Health (online August 27) analyzed 26,520 anterior cruciate ligament reconstructions in women aged 13 to 49, using the TriNetX database. Patients with documented oral contraceptive use at the time of surgery had a 25% lower risk of repeat ipsilateral reconstruction at five years (RR 0.75; p < 0.01). The abstract does not report confidence intervals.
Why it matters: this is an observational database association open to confounding (activity level, age, adherence); it raises a hormonal hypothesis about graft maturation that needs a prospective study. It does not justify prescribing contraceptives for orthopedic purposes.
https://doi.org/10.1177/19417381261477256
https://orthotw.com/2026/09/could-oral-contraceptives-help-protect-an-acl-reconstruction

3. NB1 (rhNELL-1 plus demineralized bone matrix) in lumbar fusion expands Australian sites

[Industry] [Australia]
Bone Biologics announced on September 8 that it doubled to 6 the Australian hospitals in its multicenter, prospective, randomized pilot trial of NB1 in up to 30 adults with single-level degenerative disc disease (L2–S1) undergoing transforaminal lumbar interbody fusion. Endpoints are fusion at 12 and 24 months and change in Oswestry Disability Index; the company expects enrollment to be completed by the end of 2026.
Why it matters: an enrollment update with no results, from a small company, with the comparator not specified in the release; of interest as a possible orthobiologic alternative to rhBMP-2, but there are no clinical data yet.
https://www.globenewswire.com/news-release/2026/09/08/3357635/0/en/bone-biologics-expands-trial-sites.html

Osteoporosis, rehabilitation and pediatric orthopedics

4. Marrow-homing cell therapy for severe osteoporosis: fractures down 94% in a phase 1 trial

[Clinical trial] [Published in Cell; country not detailed in the coverage reviewed]
A first-in-human phase 1 trial published in Cell treated 10 women aged 51 to 72 with severe osteoporosis and prior fractures with a single intravenous infusion of autologous mesenchymal stromal cells engineered to bind marrow E-selectin (CD44 fucosylation). Fragility fractures fell from 8 to 0.5 per year over the first two years (−94%), with histologic improvement at 4 months and improved CT trabecular quality at 2 years; DXA density did not improve at the group level. No serious adverse events were attributed to the infusion, over a median follow-up of about 6 years.
Why it matters: ten patients, no control group, most on concomitant conventional therapy with medication changes, and one of the authors (Robert Sackstein) holds intellectual property rights on the technology. An interesting biological signal, not a treatment option; a randomized trial is needed.
https://www.zmescience.com/science/news-science/a-new-living-medicine-for-osteoporosis-cut-fractures-by-94-percent/

5. One thousand PNP pediatric tibial nails implanted

[Industry] [United States]
OrthoPediatrics reported on September 22 that it has passed 1,000 implants of its rigid pediatric tibial nail (7 to 12 mm diameters, physis-sparing fixation, traditional or suprapatellar approach). Nearly 20% were 7 mm nails; the system is available in five markets, with a European launch planned for 2027.
Why it matters: a commercial milestone with no healing, limb-length or complication data; rigid nailing in adolescents with open physes still needs its own safety data.
https://orthotw.com/2026/09/orthopediatrics-surpasses-1-000-pnp-tibia-nail-implantations

There were no new verifiable studies this month on developmental dysplasia of the hip, scoliosis or rehabilitation protocols.

Cross-cutting

Regional coverage: apart from the Australian trial above, this month there were no items from Asia, Russia, the Middle East, Latin America or the Dominican Republic verifiable by date and data within the period.

Upcoming meetings and dates

  • October 14 to 17, 2026: 41st North American Spine Society (NASS) Annual Meeting, San Antonio, Texas (USA). https://www.spine.org/am
  • October 8 and 22 and November 5, 2026: online Hip Surgery Masterclass from the European Hip Society, BHS and BOA.
  • November 5 to 8, 2026: AAHKS Annual Meeting, Dallas (USA).

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.